Send to

Choose Destination
Am J Surg. 2018 Nov 28. pii: S0002-9610(18)30393-3. doi: 10.1016/j.amjsurg.2018.11.029. [Epub ahead of print]

Exclusive clinical experience with a lower profile device for resuscitative endovascular balloon occlusion of the aorta (REBOA).

Author information

University of California Riverside, California, USA. Electronic address:
University of Texas Memorial Hermann Medical Center Texas Trauma Institute, USA.
University of Maryland Shock Trauma Center Baltimore Maryland, USA.



A lower profile, FDA-approved device for aortic occlusion (AO) is available for REBOA.


Patients who received AO with the new device from February 2016 to February 2017 at 2 urban tertiary care centers were enrolled.


60 consecutive patients underwent REBOA; 44 (73.3%) following blunt trauma. 52 (88.1%) were male; mean age of 40 ± 18 years. 49 REBOAs were deployed in Zone 1, 11 in Zone 3.67.7% of patients in arrest achieved return of spontaneous circulation (ROSC). Overall in-hospital survival was 43%; 19% for patients in arrest and 69% for patients with refractory hypotension. Access and vascular procedural complications included iliac intimal injury requiring stent-graft (1), patch angioplasty of the CFA (1), and balloon ruptures (3). 5 amputations were required; 2 immediate completion amputations due to initial injury, and 3 delayed amputations after efforts to salvage severely mangled extremities were unsuccessful.


Smaller introducer sheaths for REBOA are safe and effective but do not eliminate the need for surgical common femoral artery access. Patients can benefit from REBOA with acceptable survival rates.


Aortic occlusion (AO); Hemorrhage; Resuscitative endovascular balloon occlusion of the aorta (REBOA)

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center